SYRE CIK: 1636282

Spyre Therapeutics, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
−53.7
FY22:
−80.1
FY23:
−99.9
FY24:
−157
FY25:
−169
Change from FY21 to FY25
millions USD
FY21:
−22.6
FY22:
57.0
FY23:
−108
FY24:
−353
FY25:
−143
Change from FY21 to FY25
millions USD
FY21:
1.39
FY22:
42.7
FY23:
361
FY24:
411
FY25:
309
millions USD
FY21:
−75.0
FY22:
19.4
FY23:
153
FY24:
−99.8
FY25:
−3.70
(positive)
Change from FY21 to FY24
millions USD
FY21:
−54.3
FY22:
−80.2
FY23:
−99.9
FY24:
−157
FY25:
–

All amounts in millions USD Data source:SEC EDGAR